PE20000348A1 - Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina - Google Patents

Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina

Info

Publication number
PE20000348A1
PE20000348A1 PE1999000217A PE00021799A PE20000348A1 PE 20000348 A1 PE20000348 A1 PE 20000348A1 PE 1999000217 A PE1999000217 A PE 1999000217A PE 00021799 A PE00021799 A PE 00021799A PE 20000348 A1 PE20000348 A1 PE 20000348A1
Authority
PE
Peru
Prior art keywords
statin
inhibitor
pharmaceutical composition
mmp
alkyl
Prior art date
Application number
PE1999000217A
Other languages
English (en)
Spanish (es)
Inventor
Bruce David Roth
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20000348A1 publication Critical patent/PE20000348A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE1999000217A 1998-03-17 1999-03-16 Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina PE20000348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
PE20000348A1 true PE20000348A1 (es) 2000-05-22

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000217A PE20000348A1 (es) 1998-03-17 1999-03-16 Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina

Country Status (18)

Country Link
EP (1) EP1063991A1 (ko)
JP (1) JP2002506818A (ko)
KR (1) KR20010041916A (ko)
AR (1) AR018113A1 (ko)
AU (1) AU1591699A (ko)
BR (1) BR9815745A (ko)
CA (1) CA2309588A1 (ko)
CO (1) CO5070670A1 (ko)
GT (1) GT199900039A (ko)
HN (1) HN1999000029A (ko)
MY (1) MY140504A (ko)
NZ (1) NZ505994A (ko)
PA (1) PA8469001A1 (ko)
PE (1) PE20000348A1 (ko)
SV (1) SV1999000026A (ko)
UY (1) UY25436A1 (ko)
WO (1) WO1999047138A1 (ko)
ZA (1) ZA992106B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
RU2410118C2 (ru) 2004-12-15 2011-01-27 Зольвай Фармасьютиклз Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611410A (pt) * 1995-11-02 1999-01-05 Warner Lambert Co Método e composição farmacêutica para regular a concentração de lipídios
PL186416B1 (pl) * 1996-05-17 2004-01-30 Warner Lambert Co Związek bifenylosulfonamidowy i preparat farmaceutyczny zawierający ten związek
IL128545A0 (en) * 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
PA8469001A1 (es) 2002-09-17
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23
BR9815745A (pt) 2000-11-14
NZ505994A (en) 2003-10-31
JP2002506818A (ja) 2002-03-05
SV1999000026A (es) 2000-01-18
UY25436A1 (es) 2001-10-25
CO5070670A1 (es) 2001-08-28
GT199900039A (es) 2000-09-06
HN1999000029A (es) 1999-09-29
KR20010041916A (ko) 2001-05-25
ZA992106B (en) 1999-09-30
MY140504A (en) 2009-12-31
AR018113A1 (es) 2001-10-31
WO1999047138A1 (en) 1999-09-23
EP1063991A1 (en) 2001-01-03

Similar Documents

Publication Publication Date Title
HUP0104240A2 (hu) Eljárás ateroszklerozis kezelésére egy aP2 inhibítor vagy kombinációja alkalmazásával
UY25159A1 (es) Composiciones farmacéuticas conteniendo amlodipino y una estatina
AR018777A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo.
RU2012116079A (ru) Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
IL118778A0 (en) Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an HMG-CoA reductase inhibitor
AR082930A1 (es) Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
DE69827777D1 (de) Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie
JP2018504438A5 (ko)
DE69937691D1 (de) Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin
RU2004139029A (ru) Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний
TR200302281T2 (tr) Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
WO2000048626A3 (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
PE20020850A1 (es) Utilizacion de compuestos de azetidinona sustituida para tratamiento de la sitosterolemia
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
PE20000017A1 (es) Combinaciones de estatina-eter carboxialquilico
CY1105429T1 (el) Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες
DE602004016831D1 (de) Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
PE20000348A1 (es) Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina
AR051950A1 (es) Comprimido multicapa con capas que se separan
JP2002508320A5 (ko)
AR080023A1 (es) Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
ATE444299T1 (de) Neue boronatester
UY28729A1 (es) Composiciones hipocolesterolemiantes
AR101724A1 (es) COMPOSICIÓN FARMACÉUTICA Y COMBINACIÓN TERAPÉUTICA QUE COMPRENDE UN INHIBIDOR DE LA PROTEÍNA DE TRANSFERENCIA DEL ÉSTER COLESTERILO E INHIBIDORES DE LA HMG CoA REDUCTASA

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed